Brevan Howard Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Brevan Howard Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Sell	85,545 -58,452	-41%	-$801K	0.01%	872
2026 Q1	$1.79M	Buy	143,997 +73,912	+105%	+$992K	0.02%	602
2025 Q4	$883K	Buy	70,085 +53,006	+310%	+$606K	0.01%	822
2025 Q3	$171K	Buy	+17,079	New	+$153K	﹤0.01%	1782
2025 Q1	–	Sell	-13,571	Closed	-$107K	–	1141
2024 Q4	$107K	Buy	+13,571	New	+$114K	﹤0.01%	963
2024 Q2	–	Sell	-12,817	Closed	-$77.7K	–	1045
2024 Q1	$77.7K	Sell	12,817 -35,887	-74%	-$202K	﹤0.01%	914
2023 Q4	$296K	Buy	+48,704	New	+$217K	﹤0.01%	716

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Brevan Howard Capital Management's AMRX Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Amneal Pharmaceuticals (AMRX) stake by 41% in Q2 2026, selling an estimated $801K and leaving 85,545 shares worth $1.48M. The position accounts for 0.01% of the portfolio, ranked #872.

Brevan Howard Capital Management first reported a position in AMRX in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.79M in Q1 2026. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Brevan Howard Capital Management held 85,545 shares of Amneal Pharmaceuticals worth $1.48M as of Q2 2026.
Brevan Howard Capital Management sold 58,452 Amneal Pharmaceuticals shares in Q2 2026, an estimated $801K.
Amneal Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #872 holding.
Brevan Howard Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
Brevan Howard Capital Management's Amneal Pharmaceuticals position peaked at $1.79M in Q1 2026.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.